bioAffinity Technologies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020
Net Income	-7.94	-8.15	-6.33	-7.27
Depreciation & Amortization	0.25	0.01	0	0.02
Share-Based Compensation	0.75	0.25	0.04	0.28
Other Operating Activities	0.9	3.82	4.23	4.76
Operating Cash Flow	-6.04	-4.07	-2.05	-2.21
Capital Expenditures	-0.02	-0.22	0	-0
Acquisitions	-2.19	0	0	0
Investing Cash Flow	-2.21	-0.22	0	-0
Share Issuance / Repurchase	0	6.1	0	0
Debt Issued / Paid	-0.34	0.53	3.33	1.72
Other Financing Activities	-	7.71	-	-
Financing Cash Flow	-0.34	14.34	3.33	1.72
Net Cash Flow	-8.59	10.05	1.28	-0.5
Free Cash Flow	-6.06	-4.29	-2.05	-2.21
Free Cash Flow Margin	-239.32%	-89336.50%	-	-
Free Cash Flow Per Share	-0.69	-0.95	-0.77	-0.83

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).